Prevalence of Intracardiac Shunting in Children with Sickle Cell Disease and Stroke
Objective
To determine the prevalence of potential intracardiac shunts, including patent foramen ovale (PFO), in children with sickle cell disease (SCD) and stroke.
Study design
We performed a transthoracic echocardiogram (TTE) on 40 children with SCD (39 with hemoglobin SS and 1 with sickle-beta0 thalassemia) and earlier stroke (overt stroke in 30, silent infarction in 10). We compared 3 TTE techniques: conventional 2-dimensional imaging, color Doppler ultrasound, and intravenous agitated saline contrast injection for the detection of intracardiac shunts. We also evaluated the clinical, laboratory, and radiographic findings of the children with and without shunts.
Results
We identified PFO or other potential intracardiac shunts in 10 of 40 children with SCD and earlier stroke (25%; 95% CI, 11.6-38.4). With contrasted TTE, we failed to detect potential shunts in 2 children. In a comparison group of 60 children with stroke but without SCD, retrospective review of clinical echocardiograms identified PFO in 7 of 60 (11.7%; 95% CI, 3.6-19.8). Clinical features significantly associated with the presence of intracardiac shunts were stroke in the setting of vaso-occlusive crisis (P = .026) and headache at stroke onset (P = .014).
Conclusion
One-quarter of children with SCD and stroke have potential intracardiac shunts. A combination of echocardiographic techniques is required for optimal shunt detection. Intracardiac shunting could be a risk factor for stroke in children with SCD because they are predisposed to thrombosis and elevations of right heart pressure, which could promote paradoxical embolization across an intracardiac shunt.
MRI, Magnetic resonance imaging, PFO, Patent foramen ovale, SCD, Sickle cell disease, TCD, Transcranial Doppler ultrasound, TEE, Transesophageal echocardiogram, TTE, Transthoracic echocardiogram, VOC, Vaso-occlusive crisis
To access this article, please choose from the options below
Supported by the National Heart, Lung, and Blood Institute Comprehensive Sickle Cell Center Program (U54 HL 70588) and the Children's Clinical Research Advisory Committee at Children's Medical Center Dallas. M.D. and C.Q. are supported by the North and Central Texas Clinical and Translational Science Initiative from the NIH KL2 RR024983. M.D. is supported by the First American Real Estate Information Services, Inc. The authors declare no conflicts of interest.
PII: S0022-3476(09)01026-9
doi:10.1016/j.jpeds.2009.10.012
© 2010 Mosby, Inc. All rights reserved.
